Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Stoke aims to restore developmental loss in Dravet syndrome
Stoke CEO Ian Smith said the company is seeing seizure reductions of up to 85% on top of standard-of-care medicines.
Gabrielle Masson
Mar 18, 2026 2:57pm
Novartis jettisons ph. 1 cancer candidate after 0% efficacy
Feb 19, 2026 2:45pm
Versant's Dayra dawns with $50M Biogen pact
Nov 24, 2025 10:28am
Biogen returns to its roots with a West Coast immunology outpost
Nov 18, 2025 12:25pm
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Oct 24, 2025 9:15am
Biogen discontinues all AAV gene therapy work
Sep 26, 2025 11:04am
